Cargando…

Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada

OBJECTIVE: The aim of this study was to assess the cost effectiveness of semaglutide versus dulaglutide, as an add-on to metformin monotherapy, for the treatment of type 2 diabetes (T2D), from a Canadian societal perspective. METHODS: The Swedish Institute for Health Economics Cohort Model of T2D wa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johansen, Pierre, Håkan-Bloch, Jonas, Liu, Aiden R., Bech, Peter G., Persson, Sofie, Leiter, Lawrence A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861407/ https://www.ncbi.nlm.nih.gov/pubmed/30927241 http://dx.doi.org/10.1007/s41669-019-0131-6

Ejemplares similares

A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK
por: Johansen, Pierre, et al.
Publicado: (2020)

Evaluation of the long‐term cost‐effectiveness of once‐weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK
por: Viljoen, Adie, et al.
Publicado: (2018)

The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with Type 2 Diabetes: A Cost of Control Analysis in Spain
por: Vidal, Josep, et al.
Publicado: (2020)

Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States
por: Wilkinson, Lars, et al.
Publicado: (2018)

The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia
por: Malkin, Samuel J. P., et al.
Publicado: (2019)

Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting
por: Gæde, Peter, et al.
Publicado: (2019)

Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK
por: Johansen, Pierre, et al.
Publicado: (2020)

Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses
por: Pratley, Richard E, et al.
Publicado: (2020)

Long-Term Cost-Effectiveness Analysis of Once-Weekly Semaglutide versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China
por: Ruan, Zhen, et al.
Publicado: (2022)

The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK
por: Viljoen, Adie, et al.
Publicado: (2022)

Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting
por: Stafford, Sara, et al.
Publicado: (2022)

A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA
por: Johansen, Pierre, et al.
Publicado: (2019)

Cost-Utility Analysis of Once-Weekly Semaglutide, Dulaglutide, and Exenatide for Type 2 Diabetes Patients Receiving Metformin-Based Background Therapy in China
por: Hu, Shanshan, et al.
Publicado: (2022)

Correction to: Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canaglifozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting
por: Stafford, Sara, et al.
Publicado: (2022)

Correction to: A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA
por: Johansen, Pierre, et al.
Publicado: (2019)

A population‐adjusted indirect comparison of cardiovascular benefits of once‐weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease
por: Evans, Lyndon Marc, et al.
Publicado: (2021)

Improved treatment satisfaction in patients with type 2 diabetes treated with once‐weekly semaglutide in the SUSTAIN trials
por: Jendle, Johan, et al.
Publicado: (2019)

Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia
por: Malkin, Samuel J. P., et al.
Publicado: (2018)

A survey of physician experience and treatment satisfaction prescribing once-weekly semaglutide injections for patients with type 2 diabetes in Canada
por: Qureshy, Kamran, et al.
Publicado: (2022)

Effect of once-weekly dulaglutide on renal function in patients with chronic kidney disease
por: Kim, Sungmin, et al.
Publicado: (2022)

Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands
por: Hunt, Barnaby, et al.
Publicado: (2019)

Different Effects of Once-weekly and Once-daily Administered GLP-1RA Semaglutide and Liraglutide on Bile Acid Diarrhea
por: Kårhus, Martin Lund, et al.
Publicado: (2022)

Correction: Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands
Publicado: (2020)

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes
por: Seino, Yutaka, et al.
Publicado: (2017)

Semaglutide once weekly in people with type 2 diabetes: Real‐world analysis of the Canadian LMC diabetes registry (SPARE study)
por: Brown, Ruth E, et al.
Publicado: (2020)

Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis
por: Lingvay, Ildiko, et al.
Publicado: (2020)

Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom
por: Sandhu, Hera, et al.
Publicado: (2023)

A model‐based simulation of glycaemic control and body weight when switching from semaglutide to 3.0‐ and 4.5‐mg doses of once‐weekly dulaglutide
por: Tham, Lai San, et al.
Publicado: (2021)

Cost-Minimization Analysis of Once-Weekly Versus Thrice-Weekly Epoetin Alfa for Chemotherapy-Related Anemia
por: Cremieux, Pierre Y., et al.
Publicado: (2004)

Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
por: Carlsson Petri, Kristin Cecilie, et al.
Publicado: (2018)

Once-weekly 2.4 mg Semaglutide for Weight Management in Obesity: A Game Changer?
por: Colin, Ides M, et al.
Publicado: (2022)

A Randomized Study to Compare the Effects of Once-Weekly Dulaglutide Injection and Once-Daily Glimepiride on Glucose Fluctuation of Type 2 Diabetes Mellitus Patients: A 26-Week Follow-Up
por: Li, Huiqin, et al.
Publicado: (2019)

A 24‐week study to evaluate the efficacy and safety of once‐weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD‐8)
por: Dungan, K. M., et al.
Publicado: (2016)

Long-Term Cost-Effectiveness of Subcutaneous Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes Mellitus in China
por: Liu, Lei, et al.
Publicado: (2022)

Similar efficacy and safety of once‐weekly dulaglutide in patients with type 2 diabetes aged ≥65 and <65 years
por: Boustani, M. A., et al.
Publicado: (2016)

Effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programme
por: Mathieu, Chantal, et al.
Publicado: (2018)

Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data
por: Kugler, Anne J, et al.
Publicado: (2018)

Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain
por: Garcia de Lucas, Maria Dolores, et al.
Publicado: (2022)

Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis
por: Patel, Tirath, et al.
Publicado: (2023)

Efficacy and safety of once‐weekly semaglutide versus once‐daily sitagliptin as add‐on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30‐week, double‐blind, phase 3a, randomized trial
por: Ji, Linong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lga5s6fg4mnhdi0ogedkkf72au